COVID-19: EMA Tackles Trial Data Interpretability
Sponsors Should Assess Likelihood Of Delivering Interpretable Results
A draft EU guideline explains how companies can ensure that data from ongoing clinical trials remains relevant for regulatory decision-making despite problems posed by the COVID-19 pandemic.
